Bank of America Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

United Therapeutics (NASDAQ:UTHR) had its price objective lifted by equities researchers at Bank of America from $569.00 to $626.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. Bank of America‘s price target indicates a potential upside of 6.40% from the company’s previous close.

Other research analysts have also issued reports about the company. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. UBS Group increased their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. HC Wainwright raised their target price on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, February 26th. TD Cowen lifted their target price on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $572.45.

United Therapeutics Stock Performance

United Therapeutics stock opened at $588.36 on Tuesday. The company’s 50 day simple moving average is $498.42 and its 200-day simple moving average is $474.96. United Therapeutics has a 1 year low of $266.98 and a 1 year high of $607.89. The company has a market capitalization of $25.79 billion, a price-to-earnings ratio of 21.09, a price-to-earnings-growth ratio of 1.88 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter last year, the company posted $6.19 EPS. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. Equities analysts expect that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $489.91, for a total value of $4,654,145.00. Following the completion of the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $63,688.30. This represents a 98.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $471.91, for a total value of $10,617,975.00. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 333,820 shares of company stock worth $165,495,478. Corporate insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. AE Wealth Management LLC lifted its stake in United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after buying an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC grew its holdings in United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after buying an additional 2,975 shares during the last quarter. Optimize Financial Inc purchased a new position in United Therapeutics during the third quarter worth $444,000. Simplify Asset Management Inc. acquired a new position in shares of United Therapeutics in the third quarter worth $8,351,000. Finally, Osaic Holdings Inc. raised its holdings in shares of United Therapeutics by 271.0% in the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after acquiring an additional 33,662 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase 3 TETON‑1: nebulized Tyvaso met the trial’s primary endpoint in idiopathic pulmonary fibrosis (IPF), showing a +130.1 mL change in absolute FVC vs. placebo at 52 weeks — a clear clinical readthrough that traders view as a major new market opportunity for Tyvaso. Business Wire: TETON‑1 results
• Positive Sentiment: Ralinepag + buyback momentum: earlier Phase 3 ADVANCE OUTCOMES readout for ralinepag and the company’s $2B repurchase authorization (with $1.5B in ASR agreements) have reinforced upside via both product pipeline and near‑term share‑count reduction. QuiverQuant: buyback & ralinepag
• Positive Sentiment: Analyst upgrades/price‑target lifts: multiple shops raised targets (TD Cowen to $660 among them) and at least one upgrade pushed the stock to a 52‑week high, supporting momentum and sentiment. Benzinga: target raise / upgrade
• Positive Sentiment: Bullish options flow and heavy volume: unusually large call buying and above‑average equity volume suggest short covering and speculative positioning ahead of/after the trial news (amplifies intraday moves).
• Neutral Sentiment: Market structure note — Zacks flagged that yesterday’s jump occurred on above‑average volume but noted that recent earnings‑estimate revision trends don’t necessarily imply sustained upside; useful reminder to distinguish event‑driven moves from durable estimate upgrades. Zacks: volume vs. estimate revisions
• Negative Sentiment: Execution/valuation and insider selling risks: a Bank of America analyst highlighted valuation and execution risk around Tyvaso’s IPF opportunity, and public filings show substantial insider sales over recent months — both are potential headwinds to sustaining a higher multiple. TipRanks: balanced view / risks

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.